Key points from article :
Insilico Medicine has claimed a breakthrough in AI and drug discovery.
Novel preclinical candidate addressing idiopathic pulmonary fibrosis (IPF).
20 completely novel targets discovered by AI for fibrosis, narrowed down the target to specifically address IPF.
Molecules were first generated using Structure-based Drug Design approach.
Re-designed using the Ligand-based Drug Design.
Small molecule inhibitor of a novel biological target with unprecedented mechanism of action (MOA).
Good efficacy in both in vitro and in vivo preclinical studies for IPF, and a good safety profile.
Currently progressing for IND-enabling studies and phase I clinical trials.
Targeting clinical studies by early 2022 and welcomes collaborations with pharmaceutical companies.
“Linked both biology and chemistry and nominated the preclinical candidate for a novel target..." - Alex Zhavoronkov, CEO of Insilico Medicine.
“Insilico removed staggeringly expensive and time-consuming traditional drug discovery process,” - Zhavoronkov.
